Who we are
We are a dynamic and international team of motivated scientists with the aim of commercializing a proprietary virus-based cancer therapeutic. We are currently working towards completion of a pre-clinical data package and establishment of manufacturing processes and aim to spin out from the Klinikum rechts der Isar, TUM in 2022.

Our technology
We have engineered a novel hybrid virus that targets cancer cells and causes direct lysis and activation of immune cells to attack the tumor. Our USPs include:

- Superior efficacy
- Excellent safety profile
- Simple delivery route
- Activity against many cancer types

Who you are
You are an enthusiastic master’s student in BWL/TUM Management, who is a team-player and ready to think outside the box. Your tasks will include performing market analysis and helping to solidify our business plan.

How to apply
Contact: jennifer.altomonte@tum.de